Cerebral Cavernous Malformation Clinical Trial
Official title:
CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness
Brain Cavernous Angiomas with Symptomatic Hemorrhage (CASH) are rare, but they exact a heavy burden of neurologic disability from recurrent bleeding, for which there is no proven therapy. This trial readiness project aims to address current critical obstacles in identifying cases at multiple sites, characterizing their relevant features, and measuring their outcome. The timing cannot be more opportune, with therapeutic targets already identified, exceptional collaboration among researchers and with the patient community, and several drugs ready to benefit from a track to clinical testing in the next five years.
The Trial Readiness grant mechanism, funded by NINDS, proposes to address knowledge gaps and establish a research network as infrastructure for future research. This project includes an observational cohort study of 181 patients with an operational goal of demonstrating the feasibility of screening, enrollment rates, baseline disease categorization and follow-up of CASH using common data elements at multiple sites, and to assess the following endpoints for 123 participants enrolled at centers prespecified to do prospective follow-up: (1) the rates of recurrent hemorrhage; (2) the reliability of imaging biomarkers including quantitative susceptibility mapping and permeability measures which have been shown to correlate with lesion activity, and (3) change in functional status during prospective follow-up. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04467489 -
Biomarkers of CASH
|
||
Active, not recruiting |
NCT05085561 -
The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
|
Phase 2 | |
Active, not recruiting |
NCT02946866 -
CoHOrt of Cerebral CavernOus maLformATion: multicEnter Prospective Observational Study
|
||
Recruiting |
NCT05298709 -
Functional Magnetic Resonance Imaging (fMRI) Vascular Reactivity in Cerebral Cavernous Malformations (CCM)
|
N/A | |
Active, not recruiting |
NCT02603328 -
Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial
|
Phase 1/Phase 2 | |
Terminated |
NCT05148663 -
CCM Blood Biomarker Validation Study
|
||
Completed |
NCT03589014 -
Treat_CCM: Propranolol in Familial Cerebral Cavernous Malformation
|
Phase 2 |